Evaluation of ZL-1310 for Small Cell Lung Cancer Study
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: No
CONDITION: Small Cell Lung Cancer
Learn More About This Research Study
For more information, please contact study coordinator, Madison Yockey 216-844-2023 and leave a message or complete the online form below.
Study Purpose
The purpose of this study is to evaluate the safety and tolerability of investigational drug, ZL-1310, in patients with metastatic or extensive-stage small cell lung cancer. The overall study duration is approximately 42 months but the length of time a participant will be in the study will depend on how the study drug affects the participant.
Who Can Participate
Participants 18 years of age or older diagnosed with metastatic or extensive-stage small cell lung cancer may be eligible for this study.
- STUDY20231484
- NCT06179069